Suberoylanilide Hydroxamic Acid, Fluorouracil, Leucovorin, and Oxaliplatin in Treating Patients With Progressive Metastatic or Unresectable Colorectal Cancer or Other Solid Tumors

Inclusion Criteria:

Histologically confirmed colorectal cancer
Metastatic or unresectable disease OR diagnosis of solid tumor
No known brain metastases
ECOG 0-1 OR Karnofsky 70-100%
Life expectancy > 12 weeks
Absolute neutrophil count ≥ 1,500/mm^3
WBC ≥ 3,000/mm^3
Platelet count ≥ 100,000/mm^3
Bilirubin normal
AST and ALT ≤ 3 times upper limit of normal
Creatinine normal OR creatinine clearance ≥ 60 mL/min
No symptomatic congestive heart failure
No unstable angina pectoris
No cardiac arrhythmia
Not pregnant or nursing
Negative pregnancy test
Fertile patients must use effective contraception during and for 3 months after study participation
No ongoing or active infection
No neuropathy > grade 1
No history of allergic reaction attributed to compounds of similar chemical or biological composition to study drugs
No psychiatric illness or social situation that would preclude study compliance
No psychiatric illness or social situation that would preclude study compliance
No other uncontrolled illness
Prior bevacizumab and/or cetuximab allowed
No concurrent routine or prophylactic filgrastim (G-CSF) or sargramostim (GM-CSF)
More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)
More than 4 weeks since prior radiotherapy
Recovered from prior therapy
At least 2 weeks since prior valproic acid
No concurrent combination anti-retroviral therapy for HIV-positive patients
No other concurrent investigational agents
No other concurrent anticancer therapy